Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Immune checkpoint inhibitors are now standard care for small-cell lung cancer (SCLC); however, a profound prognostic disparity persists between limited-stage (LS) and extensive-stage (ES) disease. Although clinical staging defines tumor spread, the specific molecular characteristics distinguishing LS from ES remain poorly understood, despite their potential link to immunotherapy responsiveness.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.